GlassScriptPhysician profile
Steven J Adashek
NPI 1912072232
$17,934.91
in general payments reported to CMS, 2019-2025
55 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,884 · 2020: $1,302 · 2021: $2,902 · 2022: $3,979 · 2023: $5,585 · 2024: $1,189 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073 · Consulting Fee: $3,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.63 |
| Consulting Fee | $3,794.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,332.16 | 2021-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $3,094.57 | 2021-2022 | |
| Abbvie INC. | $2,538.31 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Ibsa Pharma INC. | $1,045.40 | 2023 | Tirosint, Tirosint, Licart |
| Therapeuticsmd, INC. | $717.69 | 2019-2022 | |
| Allergan, INC. | $653.51 | 2019-2020 | |
| Pfizer INC. | $594.43 | 2019-2025 | |
| Exeltis, USA INC. | $470.22 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $412.94 | 2023-2025 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $400.87 | 2019-2024 | Trintellix |
| Bausch Health US, LLC | $303.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Daiichi Sankyo INC. | $297.14 | 2020-2024 | Injectafer |
| Lilly USA, LLC | $277.16 | 2019-2025 | Emgality, Zepbound |
| Coopersurgical, INC. | $267.38 | 2019-2025 | Paragard T 380a, Paragard T 380a, Mara Console |
| Mayne Pharma Commercial LLC | $263.59 | 2021-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Adashek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.